John Macmahon

Headquartered in Millbrae, California, Luma Therapeutics is a medical device company founded with a vision to end the suffering of people with inflammatory skin conditions, starting with psoriasis. In the United States alone there are 7.5 million people suffering from psoriasis and it affects 120 million people worldwide. Evan Anderson, our Founder and CEO, is a psoriasis patient. After trying multiple existing options for treating his own psoriasis, Evan began tinkering with coal tar, occlusive dressings and light therapy inspired by the incredible clinical results of the Goeckerman regimen. The result is Luma's first product, illuvinate. illuvinate is Luma's recently launched treatment for psoriasis. It is an FDA-cleared, home-use product and is now available in Northern California. Results are seen in as little as 6 weeks.

Enterprise Ireland is the government agency responsible for the development of Irish enterprises in world markets. We help Irish businesses to start, grow, innovate and win export sales through our international network. In this way, our organisation supports employment, regional development and sustainable economic growth.

Cytokind is the global leader in using UVB light to treat immune disorders and improve survival and the quality of life for patients. The company seeks to provide a value based care model that includes treatment therapies and support to improve longevity across a broad range of disorders. By doing so, Cytokind is disrupting the care model using UVB light in concert with digital therapeutics to create a new value and disease care paradigm to create more patient autonomy and less strain on the hospital care system. The company anticipates that their innovative approach will lead to the development of new nutraceuticals and drugs to improve chronic and acute care. We need to re-imagine our relationship with the sun. Cytokind invites you to follow the light. For more information about Cytokind and our scientific discovery, please visit: www.cytokind.net

Headquartered in Millbrae, California, Luma Therapeutics is a medical device company founded with a vision to end the suffering of people with inflammatory skin conditions, starting with psoriasis. In the United States alone there are 7.5 million people suffering from psoriasis and it affects 120 million people worldwide. Evan Anderson, our Founder and CEO, is a psoriasis patient. After trying multiple existing options for treating his own psoriasis, Evan began tinkering with coal tar, occlusive dressings and light therapy inspired by the incredible clinical results of the Goeckerman regimen. The result is Luma's first product, illuvinate. illuvinate is Luma's recently launched treatment for psoriasis. It is an FDA-cleared, home-use product and is now available in Northern California. Results are seen in as little as 6 weeks.